Products for Research Use Only
RegisterLogin

Evatanepag

CAT: 0804-HY-14839-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-14839-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Evatanepag (CP-533536) is a non-prostanoid, potent and selective EP2 receptor agonist. Evatanepag can induce local bone formation in vivo. Evatanepag can be used in the research of fractures, bone defects, asthma[1][2].
CAS Number
223488-57-1
Product Name Alternative
CP-533536 free acid
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Prostaglandin Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Endocrinology; Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/Evatanepag.html
Purity
99.78
Solubility
DMSO : ≥ 32 mg/mL
Smiles
CC(C)(C)C(C=C1)=CC=C1CN(S(C2=CN=CC=C2)(=O)=O)CC3=CC(OCC(O)=O)=CC=C3
Molecular Formula
C25H28N2O5S
Molecular Weight
468.57
Precautions
H302, H315, H319, H335
References & Citations
[1]Cameron KO, et al. Discovery of CP-533536: an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation. Bioorg Med Chem Lett. 2009 Apr 1;19 (7) :2075-8.|[2]Judith Plaza, et al. In Vitro and In Vivo Validation of EP2-Receptor Agonism to Selectively Achieve Inhibition of Mast Cell Activity. Allergy Asthma Immunol Res. 2020 Jul;12 (4) :712-728. |[3]V M Paralkar, et al. An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc Natl Acad Sci U S A. 2003 May 27;100 (11) :6736-40.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
EP

Alternative Products

CatalogName
BA5708-5.1Evatanepag
A21129-100Evatanepag 100mg
MBS5812300Evatanepag sodium
A21129-10Evatanepag 10mg
A21129-5Evatanepag 5mg
A21129-1Evatanepag 1mg
MBS131468Evatanepag? CP533536

Popular Products